Sanofi (XSWX:SAN) Other Stockholders Equity: CHF5,199 Mil (As of Dec. 2025)


XSWX:SAN Sanofi SA XSWX:SAN
87 GF Score
Price CHF73.20
GF Value CHF104.30
! 2 Warning Signs
View Full Analysis

What is Sanofi Other Stockholders Equity?

Sanofi XSWX:SAN 87 Other Stockholders Equity is CHF5,199 Mil as of Dec. 2025. GuruFocus rates XSWX:SAN with a GF Score™ of 87/100 and a GF Value™ of CHF104.30. The stock has 2 warning signs investors should review.

Sanofi's Other Stockholders Equity for the quarter that ended in Dec. 2025 was CHF5,199 Mil.

Sanofi's quarterly Other Stockholders Equity increased from Dec. 2024 (CHF4,911 Mil) to Jun. 2025 (CHF5,093 Mil) and increased from Jun. 2025 (CHF5,093 Mil) to Dec. 2025 (CHF5,199 Mil).

Sanofi's annual Other Stockholders Equity increased from Dec. 2023 (CHF4,663 Mil) to Dec. 2024 (CHF4,911 Mil) and increased from Dec. 2024 (CHF4,911 Mil) to Dec. 2025 (CHF5,199 Mil).

Sanofi Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Sanofi's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sanofi Other Stockholders Equity Chart

Sanofi Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4,584.19 4,596.81 4,662.56 4,910.80 5,199.45

Sanofi Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4,662.56 4,926.97 4,910.80 5,093.05 5,199.45
XSWX:SAN
87GF Score
Sanofi SA XSWX:SAN
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sanofi Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of CHF5,199 Mil mean?
Sanofi (XSWX:SAN) has a Other Stockholders Equity of CHF5,199 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Sanofi and its competitors.
Is Sanofi's Other Stockholders Equity too high?
Sanofi's current Other Stockholders Equity is CHF5,199 Mil. Overall, Sanofi has a GF Score™ of 87/100, reflecting its overall financial health beyond just this single metric.
How does Sanofi's Other Stockholders Equity compare to LLY and JNJ?
Sanofi's Other Stockholders Equity of CHF5,199 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Sanofi and its competitors. Sanofi's current Other Stockholders Equity is CHF5,199 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanofi stock overvalued right now?
Sanofi (XSWX:SAN) has a current Other Stockholders Equity of CHF5,199 Mil. The stock's GF Value™ is CHF104.30, compared to a current price of CHF73.20 — trading 29.8% below its estimated fair value. The current Other Stockholders Equity is CHF5,199 Mil. Sanofi's overall GF Score™ is 87/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Sanofi (XSWX:SAN), the current Other Stockholders Equity is CHF5,199 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sanofi (XSWX:SAN) Overvalued in 2026?

Based on GuruFocus' analysis, Sanofi stock appears to be undervalued. The current stock price of CHF73.20 is trading 29.8% below its estimated GF Value™ of CHF104.30.

Key valuation signals for XSWX:SAN:

  • Other Stockholders Equity: CHF5,199 Mil
  • GF Value™: CHF104.30 vs. price of CHF73.20 (29.8% below fair value)
  • GF Score™: 87/100 with 2 warning signs

No single metric tells the full story. See the XSWX:SAN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sanofi Business Description

Address 46, Avenue de la Great Army, Paris, FRA, 75017
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
87GF Score

Get the complete analysis for XSWX:SAN

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF73.20
Price
CHF104.30
GF Value